Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day, Price Target Raised to $225 From $144

11/22/2021 | 08:46am EST


ę MT Newswires 2021
All news about ALNYLAM PHARMACEUTICALS, INC.
09:18aHealth Care Stocks Decline Pre-Bell Friday
MT
08:01aAlnylam Pharmaceuticals Says Vutrisiran Met All Secondary Endpoints from HELIOS-A Phase..
MT
07:32aAlnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigation..
BU
01/20HC Wainwright Boosts Price Target on Alnylam Pharmaceuticals to $350 From $250, Keeps B..
MT
01/18Morgan Stanley Adjusts Alnylam Pharmaceuticals' Price Target to $215 from $226, Keeps O..
MT
01/17Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
AQ
01/14Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran ..
BU
01/14Alnylam Pharmaceuticals, Inc. to Present Full 18-Month Results from the HELIOS-A Phase ..
CI
01/10Alnylam Announces Preliminary Fourth Quarter and Full Year 2021 Global Net Product Reve..
AQ
01/10ALNYLAM PHARMACEUTICALS : Announces Preliminary* Fourth Quarter and Full Year 2021 Global ..
PU
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 821 M - -
Net income 2021 -760 M - -
Net cash 2021 1 321 M - -
P/E ratio 2021 -21,2x
Yield 2021 -
Capitalization 16 315 M 16 315 M -
EV / Sales 2021 18,3x
EV / Sales 2022 12,1x
Nbr of Employees 1 453
Free-Float 99,4%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 136,41 $
Average target price 211,33 $
Spread / Average Target 54,9%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet President, Chief Operating Officer & Director
Akshay K. Vaishnaw President-Research & Development
Jeffrey V. Poulton Executive VP, Chief Financial & Accounting Officer
Michael W. Bonney Independent Director
Pushkal Garg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-18.44%16 542
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831